Patents by Inventor Thomas D. Penning

Thomas D. Penning has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Macrocyclic MCL-1 Inhibitors and Methods of Use
    Publication number: 20230183261
    Abstract: The present disclosure provides for compounds of formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).
    Type: Application
    Filed: February 3, 2022
    Publication date: June 15, 2023
    Inventors: Andrew S. Judd, Aaron R. Kunzer, Chunqiu Lai, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Jesse A. Teske, Anthony Mastracchio, Xilu Wang, Cheng Ji, Michael D. Wendt, Xiaohong Song, George A. Doherty, Katja Jantos, Wilfried Braje, Andreas Kling, Frauke Pohlki, Thomas D. Penning
  • Macrocyclic MCL-1 Inhibitors and Methods of Use
    Publication number: 20200325153
    Abstract: The present disclosure provides for compounds of formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).
    Type: Application
    Filed: May 11, 2020
    Publication date: October 15, 2020
    Inventors: Andrew S. Judd, Aaron R. Kunzer, Chunqiu Lai, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Jesse A. Teske, Anthony Mastracchio, Xilu Wang, Cheng Ji, Michael D. Wendt, Xiaohong Song, George A. Doherty, Katja Jantos, Wilfried Braje, Andreas Kling, Frauke Pohlki, Thomas D. Penning
  • Macrocyclic MCL-1 inhibitors and methods of use
    Patent number: 10676485
    Abstract: The present disclosure provides for compounds of formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).
    Type: Grant
    Filed: August 15, 2018
    Date of Patent: June 9, 2020
    Assignee: AbbVie Inc.
    Inventors: Andrew S. Judd, Aaron R. Kunzer, Chunqiu Lai, Andrew J. Souers, Zhi-Fu Tao, Anthony Mastracchio, Xilu Wang, Cheng Ji, Michael D. Wendt, Xiaohong Song, George A. Doherty, Thomas D. Penning
  • Macrocyclic MCL-1 Inhibitors and Methods of Use
    Publication number: 20200010480
    Abstract: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
    Type: Application
    Filed: September 18, 2019
    Publication date: January 9, 2020
    Applicant: AbbVie Inc.
    Inventors: Patrick B. Brady, Wilfried Braje, Yujia Dai, George A. Doherty, Jane Gong, Katja Jantos, Cheng Ji, Andrew S. Judd, Aaron R. Kunzer, Chunqiu Lai, Anthony Mastracchio, Roberto M. Risi, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Jesse A. Teske, Xilu Wang, Michael D. Wendt, Yiyun Yu, Guidong Zhu, Thomas D. Penning
  • Macrocyclic MCL-1 inhibitors and methods of use
    Publication number: 20190144465
    Abstract: The present disclosure provides for compounds of formula (I) wherein A2, A3, A4, A6, A7, A8, R15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).
    Type: Application
    Filed: August 15, 2018
    Publication date: May 16, 2019
    Inventors: Andrew S. Judd, Aaron R. Kunzer, Chunqiu Lai, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Jesse A. Teske, Anthony Mastracchio, Xilu Wang, Cheng Ji, Michael D. Wendt, Xiaohong Song, George A. Doherty, Katja Jantos, Wilfried Braje, Andreas Kling, Frauke Pohlki, Thomas D. Penning
  • Macrocyclic MCL-1 inhibitors and methods of use
    Publication number: 20190055264
    Abstract: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
    Type: Application
    Filed: August 15, 2018
    Publication date: February 21, 2019
    Inventors: Patrick B. Brady, Wilfried Braje, Yujia Dai, George A. Doherty, Jane Gong, Katja Jantos, Cheng Ji, Andrew S. Judd, Aaron R. Kunzer, Chunqiu Lai, Anthony Mastracchio, Roberto M. Risi, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Jesse A. Teske, Xilu Wang, Michael D. Wendt, Yiyun Yu, Guidong Zhu, Thomas D. Penning
  • SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE
    Publication number: 20180193315
    Abstract: Compounds having a structure of Formula (IX): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1-Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.
    Type: Application
    Filed: February 28, 2018
    Publication date: July 12, 2018
    Inventors: Edward A. Kesicki, Arthur F. Kluge, Michael A. Patane, John H. Van Drie, JR., Ce Wang, Maricel Torrent, Michael L. Curtin, Todd M. Hansen, Rick F. Clark, Robin R. Frey, Zhiqin Ji, Yujia Dai, William J. McClellan, Jane Gong, Gui-dong G. Zhu, Anthony Mastracchio, Michael R. Michaelides, Thomas D. Penning, Chunqiu C. Lai
  • SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE
    Publication number: 20180071262
    Abstract: Compounds having a structure of Formula (IX): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1----Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.
    Type: Application
    Filed: October 6, 2017
    Publication date: March 15, 2018
    Applicant: AbbVie Inc.
    Inventors: Edward A. Kesicki, Arthur F. Kluge, Michael A. Patane, John H. Van Drie, JR., Ce Wang, Maricel Torrent, Michael L. Curtin, Todd M. Hansen, Rick F. Clark, Robin R. Frey, Zhiqin Ji, Yujia Dai, William J. McClellan, Jane Gong, Gui-dong G. Zhu, Anthony Mastracchio, Michael R. Michaelides, Thomas D. Penning, Chunqiu C. Lai
  • Pyridopyrimidinone inhibitors of kinases
    Patent number: 9718821
    Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R1, R2, R3, R4, and B are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as wee-1 and methods of treating diseases such as cancer.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: August 1, 2017
    Assignee: AbbVie Inc.
    Inventors: Keith W. Woods, Anthony Mastracchio, Chunqiu Lai, Viraj B. Gandhi, Thomas D. Penning
  • Pyridine CDK9 kinase inhibitors
    Patent number: 9650358
    Abstract: Disclosed are compound of Formula (Ia), wherein R2, R12, R16, J, Q, X, Y and Z are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (Ia).
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: May 16, 2017
    Assignee: AbbVie Inc.
    Inventors: Anthony Mastracchio, Milan Bruncko, Chunqiu Lai, Julie M. Miyashiro, Zhi-Fu Tao, Keith W. Woods, Thomas D. Penning, Andrew J. Souers
  • SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE
    Publication number: 20160235716
    Abstract: Compounds having a structure of Formula (IX): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1- - - -Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.
    Type: Application
    Filed: September 17, 2015
    Publication date: August 18, 2016
    Applicant: ABBVIE INC.
    Inventors: Edward A. Kesicki, Arthur F. Kluge, Michael A. Patane, John H. Van Drie, JR., Ce Wang, Maricel Torrent, Michael L. Curtin, Todd M. Hansen, Rick F. Clark, Robin R. Frey, Zhiqin Ji, Yujia Dai, William J. McClellan, Jane Gong, Gui-dong G. Zhu, Anthony Mastracchio, Michael R. Michaelides, Thomas D. Penning, Chunqiu C. Lai
  • Substituted pyrrolo[2,3-d]pyrimindines as CDK9 kinase inhibitors
    Patent number: 9346813
    Abstract: Disclosed are compound of Formula (Ia), wherein R1, R2, and R3 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions, comprising one or more compounds of Formula (Ia).
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: May 24, 2016
    Assignee: AbbVie Inc.
    Inventors: Alan S. Florjancic, Yunsong Tong, Thomas D. Penning, Andrew J. Souers, Rajeev Goswami, Zhi-Fu Tao
  • Inhibitors of poly(ADP-ribose)polymerase
    Patent number: 9283222
    Abstract: Inhibitors of poly(ADP-ribose)polymerase, ways to make them and methods of treating patients using them are disclosed.
    Type: Grant
    Filed: May 24, 2013
    Date of Patent: March 15, 2016
    Assignee: AbbVie Inc.
    Inventors: Virajkumar B. Gandhi, Vincent L. Giranda, Jianchun Gong, Thomas D. Penning, Gui-Dong Zhu
  • Pyridopyrimidinone inhibitors of kinases
    Patent number: 9181239
    Abstract: Compounds of formula (I), and pharmaceutical acceptable salts thereof, which inhibit the activity of kinases such as Wee-1 kinase are described. Also described are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: November 10, 2015
    Assignee: AbbVie Inc.
    Inventors: Anthony Mastracchio, Chunqiu Lai, Thomas D. Penning
  • Pyrrolopyridine inhibitors of kinases
    Patent number: 9181246
    Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R1a, R1b, R1c, X, and Y are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as Cdc7 and methods of treating diseases such as cancer.
    Type: Grant
    Filed: July 28, 2014
    Date of Patent: November 10, 2015
    Assignee: AbbVie Inc.
    Inventors: Thomas D. Penning, Keith W. Woods, Chunqiu Lai, Alan S. Florjancic, Yunsong Tong
  • 5-substituted indazoles as kinase inhibitors
    Patent number: 9163007
    Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, R1, R2, R3 and m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), Cdc7, AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 and nek 2.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: October 20, 2015
    Assignee: AbbVie Inc.
    Inventors: Irini Akritopoulou-Zanze, Brian D. Wakefield, Helmut Mack, Sean C. Turner, Alan F. Gasiecki, Vijaya J. Gracias, Kathy A. Sarris, Douglas M. Kalvin, Melissa J. Michmerhuizen, Qi Shuai, Jyoti R. Patel, Margaretha H. M. Bakker, Nicole Teusch, Eric F. Johnson, Peter J. Kovar, Stevan W. Djuric, Andrew J. Long, Anil Vasudevan, Dawn M. George, Lu Wang, Biqin Li, Nigel S. Moore, Adrian D. Hobson, Keith W. Woods, Julie M. Miyashiro, Steven L. Swann, Jr., Thomas D. Penning
  • Pyrrolo[2,3-B]pyridine CDK9 kinase inhibitors
    Patent number: 9073922
    Abstract: Disclosed are compounds of Formula (IIIa), wherein R1, R2, R3, X1, X2, X3, X4, X5, have any of the values defined therefore in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIIa).
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: July 7, 2015
    Assignee: AbbVie, Inc.
    Inventors: Jianchun Gong, Zhi-Fu Tao, Thomas D. Penning, Andrew J. Souers, Yunsong Tong, Guidong Zhu
  • Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases
    Patent number: 9051327
    Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein B, R1, R2, R4, and m are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as wee-1 and methods of treating diseases such as cancer.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: June 9, 2015
    Assignee: AbbVie Inc.
    Inventors: Gui-Dong Zhu, Jane Gong, Andrew S. Judd, Virajkumar B. Gandhi, Alexander R. Shoemaker, Thomas D. Penning, Michael R. Michaelides, Chunqiu Lai, Keith W. Woods
  • CDK9 kinase inhibitors
    Patent number: 8969375
    Abstract: Disclosed are compound of Formula (Ia), wherein R1A, R1, R2, R10, J, L, T, X, Y, and Z are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions, comprising one or more compounds of Formula (Ia).
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: March 3, 2015
    Assignee: AbbVie, Inc.
    Inventors: Chunqiu Lai, Zhi-Fu Tao, Keith W. Woods, Thomas D. Penning, Andrew J. Souers, Anthony Mastracchio, Julie M. Miyashiro, Yunsong Tong
  • PYRROLOPYRIDINE INHIBITORS OF KINASES
    Publication number: 20140357616
    Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R1a, R1b, R1c, X, and Y are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as Cdc7 and methods of treating diseases such as cancer.
    Type: Application
    Filed: July 28, 2014
    Publication date: December 4, 2014
    Inventors: Thomas D. Penning, Keith W. Woods, Chunqiu Lai, Alan S. Florjancic, Yunsong Tong